- Home
- NXGL vs PRTG Comparison
NXGL vs PRTG Comparison
Compare NXGL & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- PRTG
- Stock Information
- Founded
- NXGL 1997
- PRTG 1973
- Country
- NXGL United States
- PRTG British Virgin Islands
- Employees
- NXGL N/A
- PRTG N/A
- Industry
- NXGL Medical/Dental Instruments
- PRTG Oil & Gas Production
- Sector
- NXGL Health Care
- PRTG Energy
- Exchange
- NXGL Nasdaq
- PRTG Nasdaq
- Market Cap
- NXGL 19.4M
- PRTG 17.7M
- IPO Year
- NXGL 2021
- PRTG N/A
- Fundamental
- Price
- NXGL $2.52
- PRTG $7.47
- Analyst Decision
- NXGL
- PRTG
- Analyst Count
- NXGL 0
- PRTG 0
- Target Price
- NXGL N/A
- PRTG N/A
- AVG Volume (30 Days)
- NXGL 28.3K
- PRTG 908.0K
- Earning Date
- NXGL 05-13-2025
- PRTG 05-20-2025
- Dividend Yield
- NXGL N/A
- PRTG N/A
- EPS Growth
- NXGL N/A
- PRTG N/A
- EPS
- NXGL N/A
- PRTG N/A
- Revenue
- NXGL $10,228,000.00
- PRTG N/A
- Revenue This Year
- NXGL $51.39
- PRTG N/A
- Revenue Next Year
- NXGL $36.14
- PRTG N/A
- P/E Ratio
- NXGL N/A
- PRTG N/A
- Revenue Growth
- NXGL 116.01
- PRTG N/A
- 52 Week Low
- NXGL $1.84
- PRTG $2.10
- 52 Week High
- NXGL $5.10
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- NXGL 42.93
- PRTG 46.45
- Support Level
- NXGL $2.49
- PRTG $7.45
- Resistance Level
- NXGL $2.84
- PRTG $9.34
- Average True Range (ATR)
- NXGL 0.22
- PRTG 1.15
- MACD
- NXGL 0.01
- PRTG -0.42
- Stochastic Oscillator
- NXGL 13.51
- PRTG 4.72
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.